A Study of Pyridostigmine in Postural Tachycardia Syndrome

Launched by MAYO CLINIC · Dec 6, 2006

Keywords

ClinConnect Summary

This clinical trial is studying a medication called pyridostigmine to see if it can help people with Postural Tachycardia Syndrome (POTS), a condition that causes an unusually high heart rate and other symptoms when standing up. The study will last for three days and will compare the effects of pyridostigmine to a placebo (a dummy treatment that has no active medication). The researchers hope that pyridostigmine will help reduce the fast heart rate and improve blood pressure stability for those with POTS.

To participate in this trial, individuals must be diagnosed with POTS, which means they have a significant increase in heart rate when moving to an upright position and experience symptoms like lightheadedness, weakness, or palpitations. Eligible participants should be between the ages of 18 and 65 and should not be pregnant, have certain health conditions, or be taking specific medications that could interfere with the study. Throughout the trial, participants will closely monitor their symptoms and responses to the medication. This study is currently recruiting, so if you or someone you know may qualify, it could be a valuable opportunity to contribute to research on POTS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Diagnosis of postural tachycardia syndrome using the following criteria:
• • Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
• • Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
• • Both criteria must be fulfilled.
• Exclusion Criteria:
• • Pregnant or lactating women
• • Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
• • Hypothyroidism or hyperthyroidism
• • Clinically significant coronary artery disease
• • Medications that could interfere with autonomic testing
• • Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month